Seres Therapeutics Secures $25M, Cuts Costs, Extends Cash Runway into Q1 2027
Summary
Seres Therapeutics announced two critical transactions: a $25 million payment from Nestlé Health Science for future VOWST milestone buy-outs and a restructured lease agreement. This is a significant development, as the company previously issued a going concern warning and reported a cash runway only through Q3 2026 in its May 5th 10-Q filing. The $25 million cash infusion, paid in two installments in July and October 2026, combined with material lease cost reductions, extends the company's projected operating cash runway "well into the first quarter of 2027." This provides a much-needed lifeline and more time to secure additional funding or partnerships. Clinical data from an investigator-sponsored SER-155 study is expected later this month.
At the time of this announcement, MCRB was trading at $6.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.3M. The 52-week trading range was $6.56 to $29.98. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.